Perspective Therapeutics, Inc. (CATX)

1.7600 -0.0800 (-4.35%) At close: 04:00PM EDT

Perspective Therapeutics, Inc.

2401 Elliott Avenue
Suite 320
Seattle, WA 98121
United States
206-676-0900
https://www.perspectivetherapeutics.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 116

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Johan M. Spoor	CEO & Director	855.78k	N/A	1972
Mr. Jonathan R. Hunt	CFO & Co-Principal Financial Officer	944.35k	N/A	1967
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer	633.14k	N/A	1966
Mr. Shane Cobb	Executive Vice President of Operations	N/A	N/A	N/A
Mr. Mark J. Austin CPA	VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary	N/A	N/A	1987
Dr. Michael K. Schultz Ph.D.	Chief Science Officer	N/A	N/A	N/A
Mr. Andrew Bright	Executive Vice President of Brachytherapy	N/A	N/A	N/A
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer	N/A	N/A	N/A
Dr. Frances L. Johnson M.D.	Chief Innovation Officer	N/A	N/A	N/A
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Corporate governance

Perspective Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.